Latest news and press releases about ACADIA Pharmaceuticals Inc. (ACAD): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis.
Price
| Price | $27.54 |
| Market Cap | $4.7B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 12.24 |
| Price / Book | 3.62 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 91.13% |
| Operating Margin | 7.59% |
| Net Margin | 33.42% |
Related companies: ADMA · BLTE · CRNX · DYN · IMVT · LGND · MIRM
Explore sector: Healthcare · Biotechnology
More sections of ACAD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks